To further validate whether Srg3 can affect acute lung injury caused by sepsis through the NF-κB signaling pathway and ferroptosis, we administered NF-κB activator phorbol esters (PE, as 12-O-tetradecanoylphorbol-13-acetate, 100 μg/kg, intraperitoneal injection) or ferroptosis activator erastin (Era, 40 mg/kg, intraperitoneal injection) to shSrg3-treated rats (Fig. 5A). This evidence concerns the gene SMARCC1 and Sepsis.